Omega-3 fatty acids in major depressive disorder - A preliminary double-blind, placebo-controlled trial
Omega-3 fatty acids in major depressive disorder - A preliminary double-blind, placebo-controlled trial
复制标题
DOI：
10.1016/s0924-977x(03)00032-4
复制
发表时间：
2003-08-01
影响因子：
5.6
通讯作者：
Shen, WW
中科院分区：
文献类型：
--
作者：
Su, KP;Huang, SY;Shen, WW
广泛报道抑郁症患者与omega-3多不饱和脂肪酸（PUFA）异常有关，包括细胞组织含量（红细胞膜、血浆等）和膳食摄入中二十碳五烯酸和二十二碳六烯酸显着降低。然而，需要更多证据来支持其关系。在这项研究中，我们对 28 名重度抑郁症患者进行了一项为期 8 周的双盲安慰剂对照试验，在常规治疗的基础上比较 omega-3 PUFA（9.6 克/天）与安慰剂。 omega-3 PUFA 组患者在 21 项汉密尔顿抑郁量表中的得分显着低于安慰剂组患者（P
Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentacnoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (9.6 g/day) with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P